TELEPAQUE
LOE ApproachingNDAORALTABLETPriority Review
Approved
Jul 1951
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 14h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TELEPAQUE is an oral tablet diagnostic agent approved in 1951 by GE HealthCare. The product's mechanism of action and specific indications are not publicly detailed in available records. It represents a legacy diagnostic imaging product from the early nuclear medicine era.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%) suggests declining team investment and shift toward legacy product management or portfolio rationalization.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TELEPAQUE roles are heavily skewed toward legacy product management, hospital sales, and operational support rather than innovation or growth functions. Career advancement potential is limited; positions typically focus on margin protection and portfolio wind-down.
Product Manager (Legacy)Regional Sales Manager
Worked on TELEPAQUE at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.